GO:0097300 programmed necrotic cell death: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097300 programmed necrotic cell death is a genetically encoded necrotic death process triggered by endogenous signaling, including death domain receptors and Toll-like receptors.
• Unlike accidental necrosis, programmed necrotic cell death depends on defined molecular machinery such as RIPK1, RIPK3, MLKL, and gasdermins.
• Pyroptosis is a gasdermin-mediated form of programmed necrotic cell death that releases inflammatory cytokines and alarmins.
• Necroptosis is a RIPK3/MLKL-dependent programmed necrotic cell death pathway implicated in cancer, heart disease, and neurodegeneration.
• Programmed necrotic cell death shapes anti-tumor immunity and can drive immunosuppression through interleukin-1 alpha release.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect causal roles of necrotic death genes.
Description
Programmed necrotic cell death (GO:0097300) is a form of cell death that morphologically resembles necrosis but is executed by endogenous cellular signaling rather than by accidental injury. The Gene Ontology definition specifies that this process results from activation of endogenous cellular processes, such as signaling involving death domain receptors or Toll-like receptors. This distinguishes it from passive necrosis and places it alongside apoptosis and autophagic cell death as a regulated cell death modality. Researchers study GO:0097300 because it is central to inflammation, host defense, ischemia-reperfusion injury, cancer biology, and neurodegeneration. The term encompasses several mechanistically distinct subroutines, most notably pyroptosis and necroptosis, which converge on plasma membrane permeabilization and lytic release of cellular contents. Because programmed necrotic cell death is genetically encoded, it is amenable to precise CRISPR-based interrogation, making GO:0097300 a high-value target for functional genomics and therapeutic discovery.
programmed necrotic cell death At A Glance
| GO ID | GO:0097300 |
|---|---|
| GO term | programmed necrotic cell death |
| Ontology | biological_process |
| Synonym | programmed cell death by necrosis; regulated necrosis |
| Definition | A necrotic cell death process that results from the activation of endogenous cellular processes, such as signaling involving death domain receptors or Toll-like receptors. |
| Major function | Execution of genetically encoded lytic cell death that releases inflammatory cellular contents. |
| Key executioners | RIPK1, RIPK3, MLKL, gasdermin D, gasdermin E, caspase-1, caspase-8 |
| Upstream triggers | TNF receptor superfamily, Toll-like receptors, ZBP1, inflammasomes |
| Associated processes | Pyroptosis, necroptosis, inflammation, anti-tumor immunity |
What Is GO:0097300?
In our own words, GO:0097300 programmed necrotic cell death describes a necrotic cell death process that is actively triggered by endogenous cellular signaling pathways, such as those downstream of death domain receptors or Toll-like receptors, rather than by uncontrolled physical or chemical injury. It is synonymous with programmed cell death by necrosis and regulated necrosis. The process typically involves defined protein machines, including receptor-interacting kinases, mixed lineage kinase domain-like protein, and gasdermin family pore-forming proteins, which execute membrane permeabilization and lytic death.
Why Is programmed necrotic cell death Important in Cell Biology?
GO:0097300 is important because programmed necrotic cell death is a genetically encoded process that can be therapeutically modulated, unlike accidental necrosis. It is a major mechanism of inflammatory cytokine release and alarmin exposure, and it directly influences anti-tumor immunity and tissue injury. Because the pathway is executed by defined proteins such as RIPK3, MLKL, and gasdermins, it is highly tractable for CRISPR-based functional studies and drug target validation.
• Provides a genetically encoded mechanism for lytic cell death distinct from apoptosis.
• Drives release of interleukin-1 alpha and other alarmins that shape myeloid-driven immunosuppression.
• Contributes to ischemia-reperfusion injury and heart disease through regulated necrosis.
• Modulates tumor progression and anti-tumor immunity via necroptosis and pyroptosis.
• Is implicated in cerebellar Purkinje neuron death and neurodegenerative conditions.
• Serves as a source of therapeutic targets such as RIPK1, RIPK3, MLKL, and gasdermin D.
• Explains inflammatory pathology in atherosclerosis through efferocytosis and necrotic core formation.
• Enables functional genomics screens using CRISPR knockout libraries targeting death pathway genes.
• Provides mechanistic biomarkers for drug response in oncology and cardiology.
• Links innate immune sensing by Toll-like receptors to lytic cell death execution.
What Happens During programmed necrotic cell death?
Initiation by death domain receptors and Toll-like receptors
In simple terms: The process starts when specific receptors on the cell surface or inside the cell detect danger signals.
Programmed necrotic cell death is initiated by endogenous signaling through death domain receptors such as TNF receptor superfamily members or through Toll-like receptors that sense pathogen- or damage-associated molecular patterns. These receptors nucleate signaling platforms that recruit RIPK1 and related adaptors, converting an external cue into an intracellular death signal. This initiation step is genetically encoded and therefore distinct from accidental necrosis caused by direct membrane damage.
RIPK1-RIPK3 necrosome assembly
In simple terms: A protein complex called the necrosome forms and acts as a molecular switch for necrotic death.
Upon initiation, RIPK1 and RIPK3 assemble into a necrosome complex through RIP homotypic interaction motifs, a key step in necroptosis. Necrosome formation is regulated by ubiquitination, phosphorylation, and caspase-8 activity, which can suppress the pathway. The necrosome serves as the signaling hub that recruits and activates downstream executioners.
MLKL activation and membrane permeabilization
In simple terms: MLKL punches holes in the cell membrane, causing the cell to burst.
RIPK3 phosphorylates MLKL, causing MLKL to oligomerize and translocate to the plasma membrane, where it forms pores that permeabilize the cell. MLKL-mediated membrane disruption is the defining execution step of necroptosis and results in lytic release of intracellular contents. This step distinguishes programmed necrotic cell death from apoptotic cell death, which maintains membrane integrity.
Gasdermin-mediated pyroptosis
In simple terms: Gasdermin proteins form pores in the membrane as part of an inflammatory death program.
Pyroptosis is a gasdermin-mediated form of programmed necrotic cell death in which inflammatory caspases or caspase-8 cleave gasdermin D or gasdermin E to release pore-forming N-terminal fragments. Gasdermin pores permeabilize the membrane and promote release of interleukin-1 family cytokines, amplifying inflammation. This pathway links innate immune sensing to lytic death and is a major component of GO:0097300.
Release of alarmins and immune consequences
In simple terms: When the cell bursts, it spills signals that alert the immune system.
Lytic death during programmed necrotic cell death releases alarmins such as interleukin-1 alpha, which can generate myeloid-driven immunosuppression that restricts anti-tumor immunity. The release of these factors shapes the tumor microenvironment and systemic inflammatory responses. Consequently, GO:0097300 is mechanistically linked to both protective immunity and pathological inflammation.
Key Genes Involved in GO:0097300 programmed necrotic cell death
The following genes and proteins are core components or regulators of programmed necrotic cell death (GO:0097300) as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RIPK1 | Scaffold kinase that nucleates the necrosome | Central regulator of necroptosis and inflammation |
| RIPK3 | Kinase that phosphorylates MLKL | Essential necroptosis executioner and drug target |
| MLKL | Pore-forming executioner of necroptosis | Defines necroptotic membrane permeabilization |
| GSDMD | Gasdermin pore-forming protein in pyroptosis | Mediates inflammatory lytic death |
| GSDME | Gasdermin family pore-forming protein | Links caspase-3 to pyroptotic death |
| CASP1 | Inflammatory caspase activating gasdermin D | Key pyroptosis initiator |
| CASP8 | Caspase that can suppress or promote necrotic death | Regulates necroptosis and pyroptosis crosstalk |
| ZBP1 | Nucleic acid sensor activating necroptosis | Innate immune trigger of programmed necrosis |
| TLR3 | Toll-like receptor sensing double-stranded RNA | Upstream initiator of programmed necrotic death |
| TLR4 | Toll-like receptor sensing lipopolysaccharide | Links innate immunity to necrotic death |
| TNFRSF1A | Death domain receptor for TNF | Classic trigger of necroptosis |
| IL1A | Alarmin released during lytic death | Drives immunosuppression after necrotic death |
| NLRP3 | Inflammasome sensor | Activates caspase-1 and pyroptosis |
| MERTK | Efferocytosis receptor | Clears dying cells and limits necrosis in atherosclerosis |
| ATG5 | Autophagy machinery component | Crosstalk with regulated necrosis |
| BCL2 | Apoptosis regulator | Modulates cell death pathway choice |
| CASP3 | Executioner caspase | Can convert apoptosis to pyroptosis via GSDME |
How Is programmed necrotic cell death Regulated?
Programmed necrotic cell death is tightly regulated by post-translational modifications and proteolytic checkpoints. Caspase-8 activity can cleave RIPK1 and RIPK3 to suppress necroptosis, while inhibition of caspase-8 shifts death toward the necroptotic program. Phosphorylation of MLKL by RIPK3 is required for MLKL oligomerization and membrane translocation, and this step is modulated by additional kinases and phosphatases. Inflammatory caspases cleave gasdermin D to license pyroptosis, and this cleavage is controlled by inflammasome activation. Toll-like receptor and death receptor signaling provide the upstream transcriptional and post-transcriptional inputs that set the threshold for activation. Together, these regulatory layers determine whether a cell undergoes apoptosis, pyroptosis, or necroptosis.
programmed necrotic cell death and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RIPK3 | Necroptosis in cancer and inflammation | RIPK3 knockout tumor cell lines and xenografts |
| MLKL | Ischemia-reperfusion injury and heart disease | MLKL knockout cardiomyocyte models |
| GSDMD | Pyroptosis and inflammatory disease | GSDMD knockout macrophages and sepsis models |
| IL1A | Immunosuppression in tumors | IL1A knockout tumor microenvironment models |
| MERTK | Atherosclerosis and efferocytosis | MERTK knockout atherosclerosis mouse models |
Programmed necrotic cell death in cancer and anti-tumor immunity
Programmed necrotic cell death influences tumor progression and the immune response to cancer. Interleukin-1 alpha released during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity, identifying a mechanism by which necrotic death can promote tumor immune evasion. Necroptosis has been implicated in both tumor-suppressive and tumor-promoting roles depending on context, making it a complex therapeutic target. These findings support the study of GO:0097300 in immuno-oncology and drug development.
Programmed necrotic cell death in cardiovascular disease
Regulated necrosis contributes to myocardial ischemia-reperfusion injury and heart failure. Fundamental mechanisms of regulated cell death, including necroptosis, have been mapped in cardiac tissue and are considered actionable targets for cardioprotection. In atherosclerosis, defective efferocytosis leads to accumulation of dying cells and necrotic core formation, linking programmed necrotic cell death to plaque instability. These observations position GO:0097300 as a key process in cardiovascular pathology.
Programmed necrotic cell death in neurodegeneration
Programmed cell death pathways, including necrotic mechanisms, have been described in cerebellar Purkinje neurons, which are selectively vulnerable in several neurodegenerative conditions. The involvement of regulated necrosis in neuronal loss suggests that GO:0097300 may contribute to neurodegeneration beyond classical apoptosis. This provides a rationale for investigating necroptosis and pyroptosis machinery in neurological disease models.
From programmed necrotic cell death-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is RIPK3 required for necroptotic death? | RIPK3 knockout cell line |
| Does a point mutation in MLKL block membrane permeabilization? | MLKL point-mutation knock-in |
| Can a tagged RIPK1 track necrosome assembly? | Tagged knock-in of RIPK1 |
| Does gasdermin D cleavage drive pyroptosis? | GSDMD knockout and overexpression models |
| Does IL1A mediate immunosuppression after necrotic death? | IL1A knockout tumor models |
| Can CRISPR library screening identify new necrotic death regulators? | Genome-wide CRISPR knockout library screening |
How to Study the programmed necrotic cell death Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of gene function | Test requirement for necroptosis or pyroptosis |
| Point mutation knock-in | Specific residue function | Dissect MLKL or RIPK3 activation |
| Overexpression | Gain of function | Drive necrotic death in resistant cells |
| LDH release assay | Membrane permeabilization | Quantify lytic death |
| Western blot | Protein cleavage and phosphorylation | Detect gasdermin cleavage and MLKL phosphorylation |
| Immunoprecipitation | Protein complex formation | Analyze necrosome assembly |
| RNA sequencing | Transcriptional changes | Identify death pathway signatures |
| CRISPR library screening | Genome-wide gene function | Discover novel regulators of GO:0097300 |
Genetic perturbation with CRISPR
CRISPR knockout, point mutation, knock-in, and overexpression are used to test causal roles of genes in programmed necrotic cell death. Knockout of RIPK3 or MLKL abolishes necroptosis, while point mutations can separate kinase activity from scaffolding functions. These approaches are essential for distinguishing programmed necrotic cell death from apoptosis in functional assays.
Cell death and viability assays
Viability dyes, lactate dehydrogenase release, and membrane permeability assays measure lytic death characteristic of GO:0097300. These assays are often combined with caspase inhibitors to discriminate apoptosis from programmed necrosis. Time-course imaging captures the kinetics of membrane permeabilization.
Biochemical and proteomic analysis
Immunoprecipitation and western blotting detect necrosome assembly, RIPK3 phosphorylation, and MLKL oligomerization. Proteomics can identify released alarmins such as interleukin-1 alpha after lytic death. These methods provide mechanistic evidence for pathway activation.
Transcriptomic and functional genomics screens
RNA sequencing and CRISPR library screening identify transcriptional programs and novel regulators of programmed necrotic cell death. Genome-wide screens can uncover genes that sensitize or resist necrotic death. Bioinformatics integration prioritizes candidate targets for validation.
How CRISPR Can Be Used to Study GO:0097300 programmed necrotic cell death
Knockout
CRISPR knockout of RIPK3, MLKL, or GSDMD is used to test whether these genes are required for programmed necrotic cell death. Knockout cell lines provide clean genetic backgrounds for comparing apoptotic and necrotic death outcomes. These models are foundational for target validation in GO:0097300 research.
Point Mutation
Point mutation knock-in can ablate kinase activity or phospho-acceptor sites in RIPK3 or MLKL to separate signaling from execution functions. Such models help define the precise molecular requirements for necrotic death. They are also useful for testing drug resistance mutations.
Knock-in
Tagged knock-in of RIPK1, RIPK3, or MLKL enables live-cell imaging and proteomic tracking of necrosome dynamics. Knock-in reporters can quantify pathway activation in real time. These models are valuable for mechanistic studies of GO:0097300.
Overexpression
Overexpression of gasdermins or MLKL can drive lytic death in otherwise resistant cells, helping identify sufficiency of individual components. Overexpression models are also used to study cytokine release and immune consequences. They complement knockout approaches for bidirectional causal inference.
How EDITGENE Supports programmed necrotic cell death Research
Researchers studying programmed necrotic cell death-related genes often need to determine whether a candidate gene is causally involved in lytic death, inflammation, or disease progression. EDITGENE provides CRISPR-based cell model services that enable precise knockout, point mutation, knock-in, and overexpression of genes in the GO:0097300 pathway, supported by library screening and bioinformatics for functional genomics.
Contact EDITGENE today to design your custom CRISPR model for programmed necrotic cell death research.
Frequently Asked Questions About programmed necrotic cell death
What is programmed necrotic cell death?
Programmed necrotic cell death (GO:0097300) is a necrotic cell death process resulting from activation of endogenous cellular processes, such as signaling involving death domain receptors or Toll-like receptors.
What genes are involved in programmed necrotic cell death?
Key genes include RIPK1, RIPK3, MLKL, GSDMD, GSDME, CASP1, CASP8, ZBP1, TLR3, TLR4, and TNFRSF1A.
How is programmed necrotic cell death different from apoptosis?
Apoptosis maintains membrane integrity and is caspase-dependent, whereas programmed necrotic cell death involves membrane permeabilization and lytic release of cellular contents.
What is the role of MLKL in programmed necrotic cell death?
MLKL is phosphorylated by RIPK3 and oligomerizes to form membrane pores, executing necroptotic death.
What is pyroptosis?
Pyroptosis is a gasdermin-mediated form of programmed necrotic cell death that releases inflammatory cytokines.
How does programmed necrotic cell death affect cancer immunity?
Interleukin-1 alpha released during necrotic-like death can generate myeloid-driven immunosuppression that restricts anti-tumor immunity.
Can CRISPR be used to study programmed necrotic cell death?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect the pathway.
What diseases are linked to programmed necrotic cell death?
It is linked to cancer, cardiovascular disease including ischemia-reperfusion injury and atherosclerosis, and neurodegeneration.
What is the necrosome?
The necrosome is a RIPK1-RIPK3 complex that forms during necroptosis and recruits MLKL.
How can I model programmed necrotic cell death in the lab?
Common models include knockout cell lines, point mutation knock-ins, tagged reporters, overexpression lines, and CRISPR library screens.
Conclusion
GO:0097300 programmed necrotic cell death is a genetically encoded lytic death process driven by death domain receptor and Toll-like receptor signaling, executed by RIPK1, RIPK3, MLKL, and gasdermin proteins. It is mechanistically distinct from apoptosis and accidental necrosis, and it has broad implications for cancer, cardiovascular disease, and neurodegeneration. Because the pathway is genetically tractable, CRISPR-based knockout, point mutation, knock-in, overexpression, and library screening approaches are central to ongoing research. EDITGENE supports these efforts with publication-ready cell models and bioinformatics for functional validation of programmed necrotic cell death targets.
References
- 1. Shi J et al.. 2017. Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death.. Trends Biochem Sci 42(4):245-254 PMID: 27932073
- 2. D'Arcy MS. 2019. Cell death: a review of the major forms of apoptosis, necrosis and autophagy.. Cell Biol Int 43(6):582-592 PMID: 30958602
- 3. Park W et al.. 2023. Diversity and complexity of cell death: a historical review.. Exp Mol Med 55(8):1573-1594 PMID: 37612413
- 4. Hänggi K et al.. 2024. Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity.. Cancer Cell 42(12):2015-2031.e11 PMID: 39577420
- 5. Del Re DP et al.. 2019. Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease.. Physiol Rev 99(4):1765-1817 PMID: 31364924
- 6. Adkar SS et al.. 2024. Efferocytosis in atherosclerosis.. Nat Rev Cardiol 21(11):762-779 PMID: 38750215
- 7. Yan J et al.. 2022. Necroptosis and tumor progression.. Trends Cancer 8(1):21-27 PMID: 34627742
- 8. Erekat NS. 2022. Programmed cell death in cerebellar Purkinje neurons.. J Integr Neurosci 21(1):30 PMID: 35164466
